Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 749-759

  Yanagawa, T ^a   Funasaka, T ^a   Tsutsumi, S ^b   Watanabe, H ^b   Raz, A ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; APOPTOSIS INHIBITOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AUTOCRINE MOTILITY FACTOR; CASPASE 9; COLLAGEN GEL; EXOENZYME C3; GLUCOSE 6 PHOSPHATE ISOMERASE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOMYCIN C; NEUROLEUKIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACTIN FILAMENT; ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; CARCINOGENESIS; CELL ASSAY; CELL JUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN 3T3; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; MONOLAYER CULTURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCITES; AUTOCRINE MOTILITY FACTOR; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROLEUKIN; RECEPTORS, CYTOKINE; RHO GTP-BINDING PROTEINS;

EID: 11244324729     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00811     Document Type: Review

References (99)

1. Abe T, Okamura K, Ono M, Kohno K, Mori T, Hori S & Kuwano M 1993 Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. Journal of Clinical Investigation 92 54-61.
2. Akedo H, Shinkai K, Mukai M, Mori Y, Tateishi R, Tanaka K, Yamamoto R & Morishita T 1986 Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. Cancer Research 46 2416-2422.
3. Albrecht-Buehler G 1977 Phagokinetic tracks of 3T3 cells: parallels between the orientation of track segments and of cellular structures which contain actin or tubulin. Cell 12 333-339.
4. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P & Hemmings BA 1996 Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 15 6541-6551.
5. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C & Comoglio PM 1996 HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO Journal 15 6205-6212.
6. Baughan MA, Valentine WN, Paglia DE, Ways PO, Simons ER & DeMarsh QB 1968 Hereditary hemolytic anemia associated with glucosephosphate isomerase (GPI) deficiency - a new enzyme defect of human erythrocytes. Blood 32 236-249.
7. Baumann M & Brand K 1988 Purification and characterization of phosphohexose isomerase from human gastrointestinal carcinoma and its potential relationship to neuroleukin. Cancer Research 48 7018-7021.
8. Baumann M, Kappl A, Lang T, Brand K, Siegfried W & Paterok E 1990 The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Investigation 8 351-356.
9. Benlimame N, Le PU & Nabi IR 1998 Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Molecular Biology of the Cell 9 1773-1786.
10. Beutler E, West C, Britton HA, Harris J & Forman L 1997 Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells, Molecules, and Diseases 23 402-409.
11. Bikfalvi A, Klein S, Pintucci G & Rifkin DB 1997 Biological roles of fibroblast growth factor-2. Endocrine Reviews 18 26-45.
12. Boone C Sasaki M & McKee RW 1965 Characterization of an in vitro strain of Ehrlich-Lettre ascites carcinoma subjected to many periodic mouse passages. Journal of the National Cancer Institute 34 725-740.
13. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S & Reed JC 1998 Regulation of cell death protease caspase-9 by phosphorylation. Science 282 1318-1321.
14. Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, Burny A, Gras H & Tartar A 1988 The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 332 454-455.
15. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y & Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231-241.
16. Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP & Hondermarck H 2001 Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. Journal of Biological Chemistry 276 17864-17870.
17. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 32 1323-1329.
18. Dirac-Svejstrup AB, Sumizawa T & Pfeffer SR 1997 Identification of a GDI displacement factor that releases endosomal Rab GTPases from Rab-GDI. EMBO Journal 16 465-472.
19. Dunham LJ & Stewart HL 1953 A survey of transplantable and transmissible animal tumors. Journal of the National Cancer Institue 13 1299-1377.
20. Dvorak HF, Brown LF, Detmar M & Dvorak AM 1995 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology 146 1029-1039.
21. Faik P, Walker JIH, Redmill AAM & Morgan MJ 1988 Mouse glucose-6-phosphate isomerase and neuroleukin have identical 3′ sequences. Nature 332 455-457.
22. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S & Weissman AM 2001 The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. PNAS 98 14422-14427.
23. Feldman GB, Knapp RC, Order SE & Hellman S 1972 The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Research 32 1663-1666.
24. Filella X, Moiina R, Jo J, Mas E & Ballesta AM 1991 Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumour Biology 12 360-367.
25. Folkman J 1990 What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82 4-6.
26. Folkman J & Klagsbrun M 1987 Angiogenic factors. Science 235 442-447.
27. Folkman J & Shing Y 1992 Angiogenesis. Journal of Biological Chemistry 267 10931-10934.
28. Folkman J, Watson K, Ingber D & Hanahan D 1989 Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 58-61.
29. Franke TF, Kaplan DR, Cantley LC & Toker A 1997 Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 665-668.
30. Funasaka T, Haga A, Raz A & Nagase H 2001 Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochemical and Biophysical Research Communications 285 118-128.
31. Funasaka T, Haga A, Raz A & Nagase H 2002a Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid. Biochemical and Biophysical Research Communications 293 192-200.
32. Funasaka T, Haga A, Raz A & Nagase H 2002b Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. International Journal of Cancer 101 217-223.
33. Garrison RN, Galloway RH & Heuser LS 1987 Mechanisms of malignant ascites production. Journal of Surgical Research 42 126-132.
34. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR & Theodorescu D 2002 RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Research 62 6418-6423.
35. Gurney ME, Heinrich SP, Lee MR & Yin HS 1986a Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons. Science 234 566-574.
36. Gurney ME, Apatoff BR, Spear GT, Baumel MJ, Antel JP, Bania MB & Reder AT 1986b Neuroleukin: a lymphokine product of lectin-stimulated T cells. Science 234 574-581.
37. Haga A, Niinaka Y & Raz A 2000 Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochimica et Biophysica Acta 1480 235-244.
38. Haga A, Funasaka T, Niinaka Y, Raz A & Nagase H 2003 Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. International Journal of Cancer 107 707-714.
39. Hall A 1990 The cellular functions of small GTP-binding proteins. Science 249 635-640.
40. Hall A 1998 Rho GTPases and the actin cytoskeleton. Science 279 509-514.
41. Harding MA, Arden KC, Gildea JW, Gildea JJ, Perlman EJ, Viars C & Theodorescu D 2002 Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Research 62 6981-6989.
42. Harrington EA, Bennett MR, Fanidi A & Evan GI 1994 c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO Journal 13 3286-3295.
43. Harrison RA 1974 The detection of hexokinase, glucosephosphate isomerase and phosphoglucomutase activities in polyacrylamide gels after electrophoresis: a novel method using immobilized glucose 6-phosphate dehydrogenase. Analytical Biochemistry 61 500-507.
44. Kanbe K, Chigira M & Watanabe H 1994 Effects of protein kinase inhibitors on the cell motility stimulated by autocrine motility factor. Biochimica et Biophysica Acta. 1222 395-399.
45. Kanno H, Fujii H, Hirono A, Ishida Y, Ohga S, Fukumoto Y, Matsuzawa K, Ogawa S & Miwa S 1996 Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia. Blood 88 2321-2235.
46. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M & Sato Y 2000 Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19 2138-2146.
47. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH & Downward J 1997 Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO Journal 16 2783-2793.
48. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG & Stricter RM 1992 Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 1798-1801.
49. Kohn EC, Liotta LA & Schiffmann E 1990 Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells. Biochemical and Biophysical Research Communications 166 757-764.
50. Kugler W, Breme K, Kugler W, Breme K, Laspe P, Muirhead H, Davies C, Winkler H, Schr-ter W & Lakomek M 1998 Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Human Genetics 103 450-454.
51. Kumar R, Yoneda J, Bucana CD & Fidler IJ 1998 Regulation of distinct steps of angiogenesis by different angiogenic molecules. International Journal of Oncology 12 749-757.
52. Le PU, Benlimame N, Lagana A, Raz A & Nabi IR 2000 Clathrin-mediated endocytosis and recycling of autocrine motility factor receptor to fibronectin fibrils is a limiting factor for NIH-3T3 cell motility. Journal of Cell Science 113 3227-3240.
53. Leung DW, Cachianes G, Kuang WJ, Goeddel DV & Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 1306-1309.
54. Liotta LA, Kleinerman J & Saidel GM 1974 Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Research 34 997-1004.
55. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK & Schiffmann E 1986 Tumor cell autocrine motility factor. PNAS 83 3302-3306.
56. Luo JC, Yamaguchi S, Shinkai A, Shitara K & Shibuya M 1998 Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Research 58 2652-2660.
57. Luo Y, Luo Y, Long JM, Lu C, Chan SL, Spangler EL, Mascarucci P, Raz A, Longo DL, Mattson MP, Ingram DK & Weng NP 2002 A link between maze learning and hippocampal expression of neuroleukin and its receptor gp78. Journal of Neurochemistry 80 354-361.
58. Maruo N, Morita I, Shirao M & Murota S 1992 IL-6 increases endothelial permeability in vitro. Endocrinology 131 710-714.
59. Matsumoto I, Staub A, Benoist C & Mathis D 1999 Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286 1732-1735.
60. Miles AA & Miles EM 1952 Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. Journal of Physiology 118 228-257.
61. Nabi IR & Raz A 1987 Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. International Journal of Cancer 40 396-402.
62. Niinaka Y, Paku S, Haga A, Watanabe H & Raz A 1998 Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Research 58 2667-2674.
63. Nobes CD & Hall A 1995 Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81 53-62.
64. Parrizas M, Saltiel AR & LeRoith D 1997 Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. Journal of Biological Chemistry 272 154-161.
65. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS & Martin GR 1992 A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Laboratory Investigation 67 519-528.
66. Patel PS, Raval GN, Rawal RM, Patel GH, Balar DB, Shah PM & Patel DD 1995 Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer. Neoplasma 42 271-274.
67. Purring-Koch C & McLendon G 2000 Cytochrome c binding to Apaf-1: the effects of dATP and ionic strength. PNAS 97 11928-11931.
68. Quinn TP, Peters KG, De Vries C, Ferrara N & Williams LT 1993 Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. PNAS 90 7533-7537.
69. Repesh LA 1989 A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9 192-208.
70. Ridley AJ & Hall A 1992 The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70 389-399.
71. Ridley AJ, Paterson HF, Johnston CL, Diekmann D & Hall A 1992 The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70 401-410.
72. Risau W 1997 Mechanisms of angiogenesis. Nature 386 671-674.
73. Romagnoli A, Oliverio S, Evangelisti C, Iannicola C, Ippolito G & Piacentini M 2003 Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis. Biochemical and Biophysical Research Communications 302 448-453.
74. Scherle P, Behrens T & Staudt LM 1993 Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. PNAS 90 7568-7572.
75. Schröter W, Eber SW, Bardosi A, Gahr M, Gabriel M & Sitzmann FC 1985 Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg). European Journal of Pediatrics 144 301-305.
76. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS & Dvorak HF 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 983-985.
77. Seraj MJ, Harding MA, Gildea JJ, Welch DR & Theodorescu D 2000 The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clinical and Experimental Metastasis 18 519-525.
78. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H & Sato M 1990 Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene 5 519-524.
79. Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S & Raz A 1999 The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Letters 456 295-300.
80. Silletti S, Watanabe H, Hogan V, Nabi IR & Raz A 1991 Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Research 51 3507-3511.
81. Silletti S & Raz A 1993 Autocrine motility factor is a growth factor. Biochemical and Biophysical Research Communications 194 446-457.
82. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A & Freeman MR 2001 Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. American Journal of Pathology 159 651-659.
83. Suarez S & Ballmer-Hofer K 2001 VEGF transiently disrupts gap junctional communication in endothelial cells. Journal of Cell Science 114 1229-1235.
84. Tanaka N, Haga A, Uemura H, Akiyama H, Funasaka T, Nagase H, Raz A & Nakamura KT 2002 Inhibition mechanism of cytokine activity of human autocrine motility factor examined by crystal structure analyses and site-directed mutagenesis studies. Journal of Molecular Biology 318 985-997.
85. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC & Knuutila S 2001 Changes in gene expression during progression of ovarian carcinoma. Cancer Genetics and Cytogenetics 128 1-6.
86. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL & Shows TB 1991 Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 1677-1683.
87. Timar J, Silletti S, Bazaz R, Raz A & Honn KV 1993 Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE. International Journal of Cancer 55 1003-1010.
88. Torimura T, Ueno T, Kin M, Harada R, Nakamura T, Kawaguchi T, Harada M, Kumashiro R, Watanabe H, Raz A & Sata M 2001 Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of β1 Integrin. Hepatology 34 62-71.
89. Tsutsumi S, Gupta SK, Hogan V, Collard JG & Raz A 2002 Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Research 62 4484-4490.
90. Tsutsumi S, Hogan V, Nabi IR & Raz A 2003 Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Research 63 242-249.
91. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N & Williams LT 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 989-991.
92. Warburg O 1956 On the origin of cancer cells. Science 123 309-314.
93. Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR & Raz A 1991a Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. Journal of Biological Chemistry 266 13442-13448.
94. Watanabe H, Nabi IR & Raz A 1991b The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells. Cancer Research 51 2699-2705.
95. Watanabe H, Kanbe K & Chigira M 1994 Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma. Clinical and Experimental Metastasis 12 155-163.
96. Watanabe H, Takehana K, Date M, Shinozaki T & Raz A 1996 Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Research 56 2960-2963.
97. Xu W, Seiter K, Feldman E, Ahmed T & Chiao JW 1996 The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 87 4502-4506.
98. Yanagawa T, Watanabe H, Takeuchi T, Fujimoto S, Kurihara H & Takagishi K 2004 Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-β. Laboratory Investigation 84 513-522.
99. Zhi J, Sommerfeldt DW, Rubin CT & Hadjiargyrou M 2001 Differential expression of neuroleukin in osseous tissues and its involvement in mineralization during osteoblast differentiation. Journal of Bone and Mineral Research 16 1994-2004.